Tevogen Bio jumps on expanded Microsoft AI collaboration
Brief: Tevogen Bio Broadens Relationship With Microsoft To Deepen Artificial Intelligence Collaboration
Brief: Tevogen Bio Reports Third Quarter 2024 Financial
Brief: Tevogen Bio Signs LOI With Cd8 Technology To Build $50 Million R&D And Manufacturing Facility
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
Tevogen Bio soars on AI partnership with Microsoft
Brief: Tevogen Bio’S Effort In Artificial Intelligence, Tevogen Ai, Joins Microsoft For Startups, Begins Accelerating Drug Development
Tevogen Bio rises on revenue forecast of nearly $1 bln
Brief: Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast Of Nearly $1 Billion In Launch Year
Brief: Tevogen Bio Holdings Inc -Sufficient Cash To Fund Its Operations For At Least The Next 12 Months
Brief: Tevogen Bio Announces Publication Of Positive Phase I Clinical Trial Results For TVGN 489 In Blood Advances
Brief: Tevogen Bio Confirms Ongoing Efficacy Of TVGN 489 Against Dominant Flirt Strains Of SARS-CoV-2
Brief: Tevogen Bio Holdings Files Non-Timely 10-Q With US SEC
Brief: Tevogen Bio Announces Up To $50 Mln In Financing
Brief: Tevogen Bio Appoints Tapan V Shah As Head Of Investor Relations And Corporate Development
Brief: Tevogen Bio Reports Its Investigational Sars-Cov-2 Specific T Cell Therapy, Tvgn-489, Retains Activity Against The Dominant Jn.1 Variant
Brief: Tevogen Bio Prepares To Launch Genetic Predisposition Study To Study TVGN 489 Potential